Portolan Capital Management Reduces GeneDx Holdings Stake

Institutional investor cuts holdings in genomics company by nearly 73% in Q3

Mar. 14, 2026 at 9:06am

Got story updates? Submit your updates here. ›

Portolan Capital Management LLC, an institutional investor, decreased its position in GeneDx Holdings Corp. (NASDAQ:WGS) by 72.8% during the third quarter, according to a recent SEC filing. The firm now owns 44,048 shares of the company's stock, down from 162,228 shares previously.

Why it matters

GeneDx is a clinical diagnostics company specializing in genetic and genomic testing for rare and inherited disorders. The reduction in Portolan's stake could signal a shift in investor sentiment around the company's prospects, though it's unclear if this is part of a broader trend or specific to this particular investor.

The details

According to the filing, Portolan Capital Management sold 118,180 shares of GeneDx stock during the third quarter, leaving it with a position valued at $4.75 million as of the end of the period. The firm now owns about 0.15% of GeneDx's outstanding shares.

  • Portolan Capital Management decreased its GeneDx holdings during the 3rd quarter of 2025.

The players

Portolan Capital Management LLC

An institutional investor that has decreased its position in GeneDx Holdings Corp.

GeneDx Holdings Corp.

A clinical diagnostics company specializing in genetic and genomic testing for rare and inherited disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Portolan Capital Management's stake in GeneDx Holdings could signal a shift in investor sentiment around the company, though more data would be needed to determine if this is part of a broader trend or specific to this particular investor.